{"transactions":[{"id":4615065,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-10T21:48:53.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":148000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Century Therapeutics, Inc. (the \"Company\") issued to the Reporting Person stock options (the \"Options\") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan."}],"balance_after":148000,"derivative":{"exercise_price":2.03,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":148000},"source":{"system":"sec-edgar","filing":"0001452429-26-000005","document":"form4-09102026_090949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850119/000145242926000005/form4-09102026_090949.xml","form_type":"4"}},{"id":769906,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:28:05.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000119312526232667/ownership.xml","form_type":"4"}},{"id":1149125,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:33:51.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009379","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299325009379/form4.xml","form_type":"4"}},{"id":1496629,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:57:17.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011569","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299324011569/form4.xml","form_type":"4"}},{"id":1886767,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-18T18:12:44.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":2750,"price":3.73,"value":10257.5,"ownership":{"direct":true},"balance_after":2750,"source":{"system":"sec-edgar","filing":"0001062993-23-011545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299323011545/form4.xml","form_type":"4"}},{"id":1896666,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T20:29:49.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-23-010808","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299323010808/form4.xml","form_type":"4"}},{"id":2273458,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:28:04.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012307","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000106299322012307/form4.xml","form_type":"4"}},{"id":2703032,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-20T12:48:38.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":10.34,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001192482-21-000445","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000119248221000445/edgar.xml","form_type":"4"}},{"id":2961795,"issuer":{"id":144844,"kind":"organization","name":"BIOSPECIFICS TECHNOLOGIES CORP","symbol":"BSTC"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-02T09:45:12.000Z","date":"2020-12-02","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":24.78,"value":2478000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (May 28, 2020), were canceled in exchange for a cash payment of $2,478,000.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":63.72,"expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-20-032451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875622/000089924320032451/doc4.xml","form_type":"4"}},{"id":3004556,"issuer":{"id":144844,"kind":"organization","name":"BIOSPECIFICS TECHNOLOGIES CORP","symbol":"BSTC"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-19T16:15:23.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"As previously reported on a Form 4 filed on May 29, 2020 by the reporting person, the reporting person reported acquiring stock options to purchase 130,000 shares of common stock. However, BioSpecifics Technologies Corp. (the \"Company\") subsequently determined that stock options to purchase 30,000 shares of common stock under the Plan were not validly granted pursuant to the Plan because they exceeded the Plan limit on the number of stock options that may be granted to any newly-hired employee participant in any one calendar year. Accordingly, the attempted grant of these excess stock options was ineffective, and they were never granted to the reporting person. The reporting person is filing this amendment to report the correct amount of stock options acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest in four equal installments over the four-year period following the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":63.72,"expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-20-028608","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875622/000089924320028608/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-29"}},{"id":3019817,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-30T18:00:47.000Z","date":"2020-09-29","kind":"grant","acquired":true,"shares":16600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 16, 2020 subject to stockholder approval, which was obtained at the Company's special meeting of stockholders on September 29, 2020. The vesting commencement date for the option is July 16, 2020, and the option vests in equal monthly installments over 36 months, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date."}],"balance_after":16600,"derivative":{"exercise_price":11.9,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":16600},"source":{"system":"sec-edgar","filing":"0001192482-20-000742","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452429/000119248220000742/edgar.xml","form_type":"4"}},{"id":3131251,"issuer":{"id":144844,"kind":"organization","name":"BIOSPECIFICS TECHNOLOGIES CORP","symbol":"BSTC"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-29T14:32:40.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in four equal installments over the four-year period following the date of grant."}],"balance_after":130000,"derivative":{"exercise_price":63.72,"expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000899243-20-014517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875622/000089924320014517/doc4.xml","form_type":"4"}},{"id":3299098,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":1097000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":1097000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299097,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":419000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":419000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299096,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2023-12-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299095,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":87766,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":87766},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299094,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.66,"expiration_date":"2024-03-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299093,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":632000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.78,"expiration_date":"2028-05-01","underlying":"Common Stock","underlying_shares":632000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299092,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":185000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":4.11,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299091,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.59,"expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299090,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":142000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.61,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":142000},"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3299089,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-01-29T16:15:57.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":3500,"price":6.3,"value":22050.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the merger agreement (the \"Merger Agreement\") among Achillion Pharmaceuticals, Inc. (\"Achillion\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-000676","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000676/primarydocument.xml","form_type":"4"}},{"id":3391202,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-18T17:13:44.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":100234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on December 16, 2010 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter."}],"balance_after":87766,"derivative":{"exercise_price":3.1,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":100234},"source":{"system":"sec-edgar","filing":"0001562180-19-005195","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019005195/primarydocument.xml","form_type":"4"}},{"id":3391201,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-18T17:13:44.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":33250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":3.28,"expiration_date":"2019-12-18","underlying":"Common Stock","underlying_shares":33250},"source":{"system":"sec-edgar","filing":"0001562180-19-005195","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019005195/primarydocument.xml","form_type":"4"}},{"id":3391200,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-10-18T17:13:44.000Z","date":"2019-10-16","kind":"sale","acquired":false,"shares":33250,"price":6.3749,"value":211965.425,"ownership":{"direct":true},"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001562180-19-005195","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019005195/primarydocument.xml","form_type":"4"}},{"id":3391199,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-10-18T17:13:44.000Z","date":"2019-10-16","kind":"sale","acquired":false,"shares":100234,"price":6.3749,"value":638981.7266,"ownership":{"direct":true},"balance_after":36750,"source":{"system":"sec-edgar","filing":"0001562180-19-005195","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019005195/primarydocument.xml","form_type":"4"}},{"id":3391198,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-10-18T17:13:44.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":33250,"price":3.28,"value":109060.0,"ownership":{"direct":true},"balance_after":136984,"source":{"system":"sec-edgar","filing":"0001562180-19-005195","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019005195/primarydocument.xml","form_type":"4"}},{"id":3391197,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-10-18T17:13:44.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":100234,"price":3.1,"value":310725.4,"ownership":{"direct":true},"balance_after":103734,"source":{"system":"sec-edgar","filing":"0001562180-19-005195","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218019005195/primarydocument.xml","form_type":"4"}},{"id":3686964,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2019-01-25T16:50:38.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":1097000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter."}],"balance_after":1097000,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":1097000},"source":{"system":"sec-edgar","filing":"0001209191-19-005373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919119005373/doc4.xml","form_type":"4"}},{"id":3948180,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option","published_at":"2018-05-03T16:59:42.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":632000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter."}],"balance_after":632000,"derivative":{"exercise_price":3.78,"expiration_date":"2028-05-01","underlying":"Common Stock","underlying_shares":632000},"source":{"system":"sec-edgar","filing":"0001209191-18-027687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919118027687/doc4.xml","form_type":"4"}},{"id":4063630,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option","published_at":"2018-02-13T17:21:29.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":419000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter."}],"balance_after":419000,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":419000},"source":{"system":"sec-edgar","filing":"0001209191-18-009670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919118009670/doc4.xml","form_type":"4"}},{"id":4486921,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option","published_at":"2017-01-19T17:23:49.000Z","date":"2017-01-17","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period following the first anniversary of the grant date until the fourth anniversary of the grant date."}],"balance_after":185000,"derivative":{"exercise_price":4.11,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001209191-17-004611","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919117004611/doc4.xml","form_type":"4"}},{"id":4533866,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":45651,"kind":"person","name":"Truitt Joseph","position":1,"cik":"0001452429","reported_name":"Truitt Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-12-05T17:18:09.000Z","date":"2016-12-02","kind":"purchase","acquired":true,"shares":3500,"price":4.06,"value":14210.0,"ownership":{"direct":true},"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001209191-16-153426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919116153426/doc4.xml","form_type":"4"}}]}